• OPEN AN ACCOUNT
Indian Indices
Sensex
83,576.24 -604.72
( -0.72%)
Global Indices
Nasdaq
49,520.87 233.75
(0.47%)
Dow Jones
6,986.78 44.32
(0.64%)
Hang Seng
51,918.01 800.75
(1.57%)
Nikkei 225
10,123.15 78.46
(0.78%)
Forex
USD-INR
89.91 -0.02
(-0.02%)
EUR-INR
104.90 -0.20
(-0.19%)
GBP-INR
120.86 -0.43
(-0.35%)
JPY-INR
0.57 0.00
(-0.15%)

EQUITY - MARKET SCREENER

AJR Infra & Tolling Ltd
Industry :  Engineering - Turnkey Services
BSE Code
ISIN Demat
Book Value()
532959
INE181G01025
-14.1794467
NSE Symbol
P/E(TTM)
Mar.Cap( Cr.)
AJRINFRA
0
64.04
EPS(TTM)
Face Value()
Div & Yield %
0
2
0
 

Torrent Pharma to consider issuance of secured NCDs on January 5
Dec 31,2025
The proposed issuance will be within the limits already approved by the company’s Board of Directors at its meeting held on 28 July 2025, the company said in an exchange filing.

Torrent Pharma is the flagship company of the Torrent Group. It is ranked 7th in the Indian Pharmaceuticals Market and is amongst the Top 5 in the therapeutics segments of Cardiovascular (CV), Gastro Intestinal (GI), Central Nervous System (CNS) and Cosmo-Dermatology. It is a specialty-focused company with ~76% of its revenues in India from chronic & sub-chronic therapies. It has presence in 50+ countries and is ranked No. 1 amongst the Indian pharma companies in Brazil and Germany. Torrent has 8 manufacturing facilities, of which 5 are USFDA approved.

On a consolidated basis, its revenue rose 14% year-on-year to Rs 3,302 crore, compared to Rs 2,889 crore in Q2 FY25. Gross profit stood at Rs 2,502 crore, up 13% YoY, maintaining a healthy margin of 76%.

The counter shed 0.34% to Rs 3,807.60 on the BSE.